Biodistribution of model 105Rh-labeled tetradentate thiamacrocycles in rats

Nuclear Medicine and Biology

Volumn 24, Issue 1, 1997, Pages 85-92

  Li, N ^a,b   Struttman, M ^a   Higginbotham, C ^a   Grall, A J ^c   Skerlj, J F ^d   Vollano, J F ^d   Bridger, S A ^d   Ochrymowycz, L A ^c   Ketring, A R ^a,b   Abrams, M J ^d   Volkert, W A ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

^c UNIVERSITY OF WISCONSIN EAU CLAIRE   (United States)

^d Johnson and Mathey Inc   (United States)

Author keywords

14 ane thia macrocycles; 16 ane thia macrocycles; kidney; liver; Rh(III)Cl2 complexes; Sprague Dawley rats

Indexed keywords

RADIOPHARMACEUTICAL AGENT; RHODIUM; RHODIUM 105; TETRADENTATE THIAMACROCYCLE; UNCLASSIFIED DRUG; HETEROCYCLIC COMPOUND; LIGAND; RADIOISOTOPE;

ANIMAL MODEL; ARTICLE; CANCER; CONTROLLED STUDY; PHARMACOKINETICS; RADIOISOTOPE THERAPY; RAT; ANIMAL; COMPARATIVE STUDY; SPRAGUE DAWLEY RAT; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TISSUE DISTRIBUTION;

ANIMALS; HETEROCYCLIC COMPOUNDS; LIGANDS; RADIOISOTOPES; RATS; RATS, SPRAGUE-DAWLEY; RHODIUM; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TISSUE DISTRIBUTION;

EID: 0030609888     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(96)00177-1     Document Type: Article

References (22)

1. 99mTc-labeled hydrazidonicotinamide derivatized chemstatic peptide analogues for imaging focal sites of bacterial infection. J. Nucl. Med. 34: 1964-1974.
2. Bakker W. H, Albert R, Bruns C, et al. (1991) [Indium-111-DTPA-D-Phe-1] octreotide, a potential radiopharmaceutical for imaging somatostin receptor positive tumors: Synthesis, radiolabeling and in vitro validation. Life Sci. 49, 1583-1591.
3. 3 = 1,5,9,13-tetrathiacyclohexadecane]. J. Chem. Soc. Dalton Trans. 1675-1680.
4. Chatal J-F., Peltier P., et al. (1992) Does immunoscintigraphy serve clinical needs effectively? Is there a future for radioimmunotherapy? Eur. J. Nucl. Med. 19, 205-213.
5. 99m to study high-capacity and low-capacity biochemical systems. Eur. J. Nucl. Med. 22, 249-263; 1995.
6. Eckelman W. C., and Gibson R. E. (1993) The design of site-directed radiopharmaceuticals for use in drug discovery. In: Nuclear Imaging in Drug Discovery, Development, and Approval (Edited by Gibson R. E., Dannals R. F. and Siegl P. K. S.). pp. 113-134. Birkhauser.
7. Fischman A. J., Babich J. W. and Strauss H. W. (1993) A ticket to ride: Peptide radiopharmaceuticals. J. Nucl. Med. 34, 2253-2263.
8. Fritzberg A. R., Gustafson L. M., Hylarides M. D., and Reno J. M. (1994) Molecular targeting chemistry in rational drug design In: Chemical and Structural Approaches to Rational Drug Design (Edited by Weiner D. B., and Williams W. V.). pp. 125-158. CRC Press, Boca Raton, FL.
9. 105Rh as a potential radiotherapeutic agent. Appl. Radiat. Isot. 39, 257-260.
10. 105Rh(III) chloride complexation with [14]aneN2S2 and [14]aneN4 macrocycles in aqueous solution. Radiochimica Acta.
11. Makrigiorgos G., Adelstein S. J., Kassis A. I. (1990) Auger electron emitters: insights gained from in vitro experiments. Rad. & Envir. Biophysics 29, 75-91.
12. Meredith R. F., Bueschen A. F., et al. (1994) Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49. J. Nucl. Med. 35, 1017-1022.
13. O'Neil J. P., Carlson K. E., Anderson C. J., et al. (1994) Progestin radiopharmaceuticals labeled with Tc and Re: (1994) Synthesis binding affinity and in vivo distribution of a new progestin N2S2-metal complex. Biocon. Chem. 5, 181-193.
14. Ochrymowycz L. A., Mak C. P., Michna J. D. (1974) Synthesis of macrocyclic polythiaethers. J. Org. Chem. 39, 2079-2084.
15. Press O. W., Appelbaum F. R., Eary J. F. and Bestein I. D. (1994) Radiolabeled antibody therapy of lymphomas. Bio. Ther. Cancer Updates 4, 1-3.
16. Schubiger P. A., Alberto R and Smith A. (1996) Vehicles, chelators, and radionuclides: Choosing the "building blocks" of an effective therapeutic radioimmunoconjugate. Bioconj. Chem. 7, 165-179.
17. Sharkey R. M., Blumenthal R. D. and Goldenberg D. M. (1995) Development of cancer radioimmunotherapy and its potential use as an adjuvant treatment. In: Cancer Therapy With Radiolabeled Antibodies (Edited by Goldenberg D. M). CRC Press.
18. Trevena I., Nordion, International. (Personal communication).
19. Troutner D. E. (1987) Chemical and physical properties of radionuclides. Nucl. Med. Biol. Int. J. Radiat. Appl. Inst. [B] 14, 171-176.
20. 211AT]astabobenzylguanidine: Further evaluation of potential therapeutic agent. Int. J. Cancer 57, 908-913.
21. Venkatesh M, Goswami N, Volkert W. A., Schlemper E. O., Ketring A. R., Barnes C. L. and Jurisson S. (1996) An Rh-105 complex of tetrathiacyclohexadecane diol with potential for formulating bifunctional chelates. Nucl. Med. Biol. 23, 33-40.
22. Volkert W. A., Goeckeler W. F., Ehrhardt G. J., Ketring A. R. Therapeutic radionuclides: Production and decay property considerations. J. Nucl. Med. 32, 174-185.